Review
doi: 10.1158/1535-7163.MCT-16-0050.
Epub 2016 Jul 12.
Concepts to Target MYC in Pancreatic Cancer
Affiliations
- PMID: 27406986
- DOI: 10.1158/1535-7163.MCT-16-0050
Item in Clipboard
Review
Concepts to Target MYC in Pancreatic Cancer
Mol Cancer Ther.
2016 Aug.
Abstract
Current data suggest that MYC is an important signaling hub and driver in pancreatic ductal adenocarcinoma (PDAC), a tumor entity with a strikingly poor prognosis. No targeted therapies with a meaningful clinical impact were successfully developed against PDAC so far. This points to the need to establish novel concepts targeting the relevant drivers of PDAC, like KRAS or MYC. Here, we discuss recent developments of direct or indirect MYC inhibitors and their potential mode of action in PDAC. Mol Cancer Ther; 15(8); 1792-8. ©2016 AACR.
©2016 American Association for Cancer Research.
Similar articles
-
Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.Mol Cancer Ther. 2017 Sep;16(9):1729-1738. doi: 10.1158/1535-7163.MCT-17-0009. Epub 2017 Jun 15. Mol Cancer Ther. 2017. PMID: 28619758
-
FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.J Cell Biochem. 2020 Mar;121(3):2458-2466. doi: 10.1002/jcb.29468. Epub 2019 Nov 6. J Cell Biochem. 2020. PMID: 31692063
-
β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.Cancer Lett. 2016 Apr 1;373(1):67-76. doi: 10.1016/j.canlet.2016.01.026. Epub 2016 Jan 21. Cancer Lett. 2016. PMID: 26803058
-
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.J Hematol Oncol. 2020 Oct 2;13(1):130. doi: 10.1186/s13045-020-00958-3. J Hematol Oncol. 2020. PMID: 33008426 Free PMC article. Review.
-
Critical role of oncogenic KRAS in pancreatic cancer (Review).Mol Med Rep. 2016 Jun;13(6):4943-9. doi: 10.3892/mmr.2016.5196. Epub 2016 Apr 27. Mol Med Rep. 2016. PMID: 27121414 Review.
Cited by
-
Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.World J Gastroenterol. 2020 Jul 14;26(26):3737-3749. doi: 10.3748/wjg.v26.i26.3737. World J Gastroenterol. 2020. PMID: 32774054 Free PMC article.
-
Systemic deuteration of SCID mice using the water-isotopologue deuterium oxide (D2 O) inhibits tumor growth in an orthotopic bioluminescent model of human pancreatic ductal adenocarcinoma.Mol Carcinog. 2023 May;62(5):598-612. doi: 10.1002/mc.23509. Epub 2023 Feb 2. Mol Carcinog. 2023. PMID: 36727657 Free PMC article.
-
PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression.Transl Oncol. 2020 Jul;13(7):100776. doi: 10.1016/j.tranon.2020.100776. Epub 2020 May 15. Transl Oncol. 2020. PMID: 32422575 Free PMC article.
-
PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer.J Exp Clin Cancer Res. 2019 Nov 12;38(1):463. doi: 10.1186/s13046-019-1466-7. J Exp Clin Cancer Res. 2019. PMID: 31718704 Free PMC article.
-
Targeting liquid-liquid phase separation in pancreatic cancer.Transl Cancer Res. 2019 Feb;8(1):96-103. doi: 10.21037/tcr.2019.01.06. Transl Cancer Res. 2019. PMID: 35116738 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
